Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?
Journal of Nuclear Medicine · 29.10.2026 · jnumed.126.273292
DOI: 10.2967/jnumed.126.273292 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 29.10.2026. Verfasst von Alev Çınar. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
TO THE EDITOR: I read with great interest the recently published RE-LuPSMA protocol by Nikitas et al. describing a prospective phase 2 study evaluating retreatment with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer who previously benefited from prostate-
Zitieren
APA
Çınar, A. (2026). Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?. Journal of Nuclear Medicine, jnumed.126.273292. https://doi.org/10.2967/jnumed.126.273292
Vancouver
Çınar A. Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?. Journal of Nuclear Medicine. 2026:jnumed.126.273292. doi:10.2967/jnumed.126.273292
BibTeX
@article{nar2026,
author = {Çınar, Alev},
title = {Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?},
journal = {Journal of Nuclear Medicine},
year = {2026},
pages = {jnumed.126.273292},
doi = {10.2967/jnumed.126.273292}
}
EUVIMED